The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chukanova E.I.

Pirogov Russian National Research Medical University (Pirogov University)

Chukanova A.S.

Pirogov Russian National Research Medical University (Pirogov University)

Ageless

Authors:

Chukanova E.I., Chukanova A.S.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2025;(11): 98‑100

Read: 94 times

Buy for 300₽
Contact the author
Table of contents

To cite this article:

Chukanova EI, Chukanova AS. Ageless. Non Nocere. New Therapeutic Journal. 2025;(11):98‑100. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

Brain aging and mechanisms of geroprotection.

Authors:

Chukanova E.I.

Pirogov Russian National Research Medical University (Pirogov University)

Chukanova A.S.

Pirogov Russian National Research Medical University (Pirogov University)

Close metadata

References:

  1. Ministry of Health of the Russian Federation. Useful resources. Structure and key activities of the national project “New technologies for preserving health” [Electronic resource]. Date of publication: 08.08.2025. Date of access: 01.10.2025. https://minzdrav.gov.ru/poleznye-resursy/natsionalnye-proekty-rossii-prodolzhitelnaya-i-aktivnaya-zhizn-novye-tehnologii-sberezheniya-zdorovya/struktura-i-klyuchevye-meropriyatiya-natsionalnogo-proekta-novye-tehnologii-sberezheniya-zdorovya
  2. Gusev E.I., Chukanova E.I., Chukanova A.S. Chronic cerebrovascular insufficiency (risk factors, pathogenesis, clinical presentation, treatment). – Moscow: OOO AST 345, 2018. – 203 p. 
  3. Hedman AM, van Haren NE, Schnack HG, Kahn RS, Hulshoff Pol HE. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp. 2012 Aug;33(8):1987-2002. https://doi.org/10.1002/hbm.21334
  4. Chukanova EI, Chukanova AS, Andrianov DD. Arterial hypertension is an oxidative stress, as a pathogenetic target for the treatment of chronic cerebrovascular insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1):84-90. (In Russ.) https://doi.org/10.17116/jnevro202512501184
  5. Okovity S.V., Radko S.V., Shustov E.B. Succinate receptors (SUCNR1) as a promising target for pharmacotherapy. Chemical and pharmaceutical journal. 2015;49(9):4-7.  https://doi.org/10.30906/0023-1134-2015-49-9-3-7
  6. Hamel D, Sanchez M, Duhamel F, et al. G-Protein-coupled receptor 91 and succinate are key contributors in neonatal postcerebral hypoxia-ischemia recovery. Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):285-293.https://doi.org/10.1161/ATVBAHA.113.302131 
  7. Voronina T.A. Free-radical and mitochondrial theories of aging. Effects of Mexidol as a geroprotector and geriatric agent. In: Antioxidants. From Molecule to Treatment Practice. Edited by T.A. Voronina, M.M. Tanashyan, A.I. Fedina, et al. Moscow: Media Sfera Publishing House, 2024, pp. 172-189. 
  8. Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017 Jun 1;36(11):1474-1492. https://doi.org/10.15252/embj.201695810
  9. Fumagalli M, Lombardi M, Gressens P, Verderio C. How to reprogram microglia toward beneficial functions. Glia. 2018 Dec;66(12):2531-2549. https://doi.org/10.1002/glia.23484
  10. Kirova Y. I., Germanova E. L. New aspects of the energy-tropic action of mexidol. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 2018;62(4):36-40.  https://doi.org/10.25557/0031-2991.2018.04.36-40
  11. Voronina TA, Litvinova SA, Gladysheva NA, Shulyndin AV. The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22-33. (In Russ., In Engl.) https://doi.org/10.17116/jnevro202512505122
  12. Shchulkin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(2):35-39. (In Russ.) https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2012/2/031997-729820120206
  13. Kirova YuI, Shakova FM, Germanova EL, Romanova GA, Voronina TA. The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(1):62-69. (In Russ.) https://doi.org/10.17116/jnevro202012001162
  14. Martynov AI, Tanashyan MM, Malyavin AG, et al. Resolution of the expert council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Russian Journal of Preventive Medicine. 2024;27(11):85-93. (In Russ.) https://doi.org/10.17116/profmed20242711185
  15. Shchulkin AV, Chernykh IV, Abalenikhina YuV, Gatsanoga MV, Andryushina OA, Kruzhalov NA, Yakusheva EN. The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):107-112. (In Russ., In Engl.) https://doi.org/10.17116/jnevro2025125021107
  16. Fedin AI, Zaharov VV, Tanashyan MM, Chukanova EI, Madzhidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ., In Engl.) https://doi.org/10.17116/jnevro20211211117
  17. Zakharov V.V., Ostroumova O.D., Kochetkov A.I., Klepikova M.V., Fedin A.I. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Therapy. 2023;9(1):145-159.  https://doi.org/10.18565/therapy.2023.1.145-159
  18. Zaharov VV, Tkacheva ON, Mkhitaryan EA, Fedin AI. Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11-2):73-80. (In Russ., In Engl.) https://doi.org/10.17116/jnevro202212211273
  19. Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3-2):55-65. (In Russ., In Engl.) https://doi.org/10.17116/jnevro20171173255-65
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.